SCHEMBL2200002

SCHEMBL2200002

CCN(CC)C1CCN(C(=O)c2c(C)nn(-c3cccc(OC(F)(F)F)c3)c2C)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
GPR119 Q8TDV5 1/20 0.44
SCN9A Q15858 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
POLR1A O95602 1/20 0.41
NOTUM Q6P988 1/20 0.41
OPRM1 P35372 1/20 0.41
CACNA2D1 P54289 1/20 0.41
PIM1 P11309 1/20 0.40
PDE4D Q08499 2/20 0.40
NPY5R Q15761 1/20 0.40
PDE4B Q07343 1/20 0.40
RAB9A P51151 2/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
JAK1 P23458 1/20 0.39
KDM1A O60341 1/20 0.39
CACNA1B Q00975 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201573 0.89 KMT2A (0.43) KMT2AGPR119POLR1ANPSR1JAK1
SCHEMBL2197635 0.87 KMT2A (0.53) KMT2AGPR119SCN9ASCN10ANOTUM
SCHEMBL2203098 0.85 KMT2A (0.45) KMT2AGPR119SCN9ASCN10ANOTUM
SCHEMBL2203102 0.85 KMT2A (0.45) KMT2AGPR119SCN9ASCN10ANOTUM
SCHEMBL27788063 0.85 KMT2A (0.49) KMT2ASCN9ASCN10ANOTUMOPRM1
SCHEMBL2197614 0.85 KMT2A (0.44) KMT2AGPR119POLR1APDE4DPDE4B
SCHEMBL12510462 0.83 KMT2A (0.43) KMT2AGPR119POLR1ANOTUMPDE4D
SCHEMBL2201158 0.81 KMT2A (0.41) KMT2AGPR119POLR1APDE4DPDE4B
SCHEMBL2202045 0.81 KMT2A (0.47) KMT2ASCN9ASCN10ANOTUMPIM1
SCHEMBL2201907 0.80 KMT2A (0.52) KMT2ASCN9ANOTUMRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 KMT2A 4057/4885GPR119 255/4885SCN9A 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.